Skip to main content

Advertisement

SpringerLink
Log in

Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study

  • Biotechnologically Relevant Enzymes and Proteins
  • Published:
Applied Microbiology and Biotechnology Aims and scope Submit manuscript

Abstract

The HER2/neu proto-oncogene encodes a 185-kDa trans-membrane glycoprotein kinase with extensive homology to the epidermal growth factor receptor and plays a key role in the transformation and growth of malignant tumors. To date, two antibody drugs targeting HER2/neu have been developed successfully. In order to reduce the cost and the time of clinical treatment, we produced a fusion protein composed of human beta defensin 2 (hBD2) and anti-HER2/neu single-chain variable fragment (scFv 4D5), which is capable of specifically targeting, significantly inhibiting, and promptly killing HER2/neu-positive cancer cells. The recombinant protein was expressed in Escherichia coli using the small ubiquitin-related modifier (SUMO) as the molecular chaperone, and the optimal expression level reached to 40.2 % of the total supernatant protein. After purifying by Ni-NTA affinity chromatography, the fusion protein was cleaved with a SUMO-specific protease to obtain hBD2–4D5, which was further purified by Ni-NTA affinity chromatography. The purity of hBD2–4D5 was higher than 95 %, and the yield was 19 ± 2 mg/L in flask fermentation. The cell number count and flow cytometry results showed that hBD2–4D5 exerted cytotoxic and anti-proliferative effects on HER2/neu-positive breast cancer cell line, SKBR-3. The results of scanning electron microscope and transmission electron microscope observation indicated that hBD2–4D5 could induce intracellular ultrastructure changes and cell necrosis by disrupting the cell membrane. Immunofluorescence analysis showed that hBD2–4D5 could bind to SKBR-3 cells and further be internalized into the cytoplasm. Moreover, hBD2–4D5 could also mediate apoptosis of SKBR-3 cells by up-regulating the ratio of Bax to Bcl-2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  • Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12:4036–4042

    Article  CAS  Google Scholar 

  • Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW (2001) Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 167:6644–6653

    CAS  Google Scholar 

  • Bowdish DM, Davidson DJ, Hancock RE (2006) Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbio Immunol 306:27–66

    Article  CAS  Google Scholar 

  • Bruell D, Stöcker M, Huhn M, Redding N, Küpper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R, Finnern R, Barth S (2003) The recombinant anti-EGF receptor immunotoxin 425 (scFv)-ETA′ suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23:1179–1186

    CAS  Google Scholar 

  • Butt TR, Edavettal SC, Hall JP, Mattern MR (2005) SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif 43:1–9

    Article  CAS  Google Scholar 

  • Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K, Saito H, Nagaoka I, Ikeda S, Okumura K, Ogawa H (2007) Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur J Immunol 37:434–444

    Article  CAS  Google Scholar 

  • Corrales-Garcia LL, Possani LD, Corzo G (2011) Expression systems of human β-defensins: vectors, purification and biological activities. Amino Acids 40:5–13

    Article  CAS  Google Scholar 

  • Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139

    Article  CAS  Google Scholar 

  • Fadnes B, Rekdal O, Uhlin-Hansen L (2009) The anticancer activity of lytic peptides is inhibited by heparin sulfate on the surface of the tumor cells. BMC Cancer 9:183

    Article  Google Scholar 

  • Ganz T (2003) Defensins: antimicrobial peptides of innate immunity. Nature Rev Immunol 3:710–720

    Article  CAS  Google Scholar 

  • Harder J, Bartels J, Christophers E, Schroder JM (1997) A peptide antibiotic from human skin. Nature 387:861

    Article  CAS  Google Scholar 

  • Huang Y, Su Z, Li Y, Zhang Q, Cui L, Su Y, Ding C, Zhang M, Feng C, Tan Y, Feng W, Li X, Cai L (2009) Expression and purification of GST-SUMO-MT fusion protein, and its neuronal and hepatic protection against d-galactose-induced oxidative damage in mouse model. J Pharmacol Exp Ther 329:469–478

    Article  CAS  Google Scholar 

  • Jung S, Mysliwy J, Spudy B, Lorenzen I, Reiss K, Gelhaus C, Podschun R, Leippe M, Grotzinger J (2011) Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules. Antimicrob Agents Chemother 55:954–960

    Article  CAS  Google Scholar 

  • Kohlgraf KG, Ackermann A, Lu X, Burnell K, Bélanger M, Cavanaugh JE, Xie H, Progulske-Fox A, Brogden KA (2010) Defensins attenuate cytokine responses yet enhance antibody responses to Porphyromonas gingivalis adhesins in mice. Future Microbiol 5:115–125

    Article  CAS  Google Scholar 

  • Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M (2003) Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res 23:4443–4449

    CAS  Google Scholar 

  • Lichtenstein A, Ganz T, Selsted ME, Lehrer RI (1986) In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 68:1407–1410

    CAS  Google Scholar 

  • Liu L, Roberts AA, Ganz T (2003) By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. J Immunol 170:575–580

    CAS  Google Scholar 

  • Ma XT, Xu B, An LL, Dong CY, Lin YM, Shi Y, Wu KF (2006) Vaccine with beta-defensin 2 transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses. Can Res 66:1169–1176

    Article  CAS  Google Scholar 

  • Ma C, Li Y, Li Z, Huang H, Xu K, Xu H, Bai J, Li X, Zhao G (2012) Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli. Protein Expr Purif 83:1–7

    Article  CAS  Google Scholar 

  • Markeeva N, Lysovskiy I, Zhuravel E, Soldatkina M, Lyzogubov V, Usenko V, Potapov V, Pogrebnoy P (2005) Involvement of human beta-defensin-2 in proliferation of transformed cells of human cervix. Exp Oncol 27:308–313

    CAS  Google Scholar 

  • Moulder SL, Arteaga CL (2003) A phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 4:142–145

    Article  CAS  Google Scholar 

  • Niyonsaba F, Ogawa H, Nagaoka I (2004) Human beta defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 111:273–281

    Article  CAS  Google Scholar 

  • Oren A, Ganz T, Liu L, Meerloo T (2003) In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 74:180–182

    Article  CAS  Google Scholar 

  • Pazgiera M, Hooverb DM, Yang D, Lu W, Lubkowski J (2006) Human β-defensins. Cell Mol Life Sci 63:1294–1313

    Article  Google Scholar 

  • Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG (1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675–5682

    CAS  Google Scholar 

  • Selsted ME, Ouellette AJ (2005) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6:551–557

    Article  CAS  Google Scholar 

  • Semple F, Webb S, Li HN, Patel HB, Perretti M, Jackson IJ, Gray M, Davidson DJ, Dorin JR (2010) Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 40:1073–1078

    Article  CAS  Google Scholar 

  • Tsutsumi SH, Suzuki K, Akahori Y (2011) Antibody-dependent cell-mediated cytotoxicity is induced by a single-chain Fv–protein III fusion in the presence of a rabbit anti-protein III polyclonal antibody. Immunol Letters 136:44–48

    Article  Google Scholar 

  • Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F (2005) HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study Oncology 68:154–161

    CAS  Google Scholar 

  • Wang YS, Wang GQ, Wen YJ, Wang L, Chen XC, Chen P, Kan B, Li J, Huang C, Lu Y, Zhou Q, Xu N, Li D, Fan LY, Yi T, Wu HB, Wei YQ (2007) Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta defensin 2 and mFlk-1. Clin Cancer Res 13:6779–6787

    Article  CAS  Google Scholar 

  • Winter J, Wenghoefer M (2012) Human defensins: potential tools for clinical applications. Polymers 4:691–709

    Article  Google Scholar 

  • Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ (1999) Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525–528

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grant of the Science Foundation of Wenzhou in China (No. Y20090279), grant of Guangdong Provincial Department of Science and Technology (No. 2009B080701090), the Program for New Century Excellent Talents in University (NCET-08-0611) and the Academy of Sciences comprehensive strategic cooperation of Guangdong Province in China (No. 2010B090301016).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Biomedicine, Jinan University, Guangzhou, 510632, China

    Minjing Zhang, Zhuangwei Qiu, Yinyu Li, Yan Yang, Qihao Zhang, Qi Xiang, Zhijian Su & Yadong Huang

  2. Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou, 510632, China

    Minjing Zhang, Zhuangwei Qiu, Yinyu Li, Yan Yang, Qihao Zhang, Qi Xiang, Zhijian Su & Yadong Huang

Authors
  1. Minjing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhuangwei Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yinyu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qihao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qi Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhijian Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yadong Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhijian Su or Yadong Huang.

Additional information

Minjing Zhang and Zhuangwei Qiu contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, M., Qiu, Z., Li, Y. et al. Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study. Appl Microbiol Biotechnol 97, 3913–3923 (2013). https://doi.org/10.1007/s00253-012-4257-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00253-012-4257-z

Keywords

Search

Navigation